– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily Dosing Across a Range of Doses – – Alixorexton Was Generally Well Tolerated at All Doses Tested – – Company to Host Investor...
Hence then, the article about alkermes presents detailed positive results from vibrance 1 phase 2 study of alixorexton in patients with narcolepsy type 1 at world sleep congress 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 )
Also on site :
- Kentucky congressman announces death of longtime staffer, campaign manager
- EastEnders airs reunion for 'Witches of Walford', shock arrest, and Cindy & Max hook-up for Christmas 2025
- Camarillo man arrested after stolen camera reactivated and installed on the exterior of a home